A Dark Vector Cognition product

Cover and table of contents

106K characters. Original on sec.gov ·

Cover and table of contents

The 37 tables in Cover and table of contents as one CSV, figures in aligned columns. For subscribers: paste your API key. One API call. Plans from $19 a month, see pricing.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 10-Q

(Mark One)

xQUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2026

OR

oTRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to

Commission File No. 1-2189

ABBOTT LABORATORIES

An Illinois CorporationI.R.S. Employer Identification No.
36-0698440

100 Abbott Park Road

Abbott Park, Illinois 60064-6400

Telephone: (224) 667-6100

Securities Registered Pursuant to Section 12(b) of the Act:

Title of Each ClassTrading Symbol(s)Name of Each Exchange on Which Registered
Common Shares, Without Par ValueABTNew York Stock Exchange NYSE Texas

Indicate by check mark whether the registrant: (l) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of l934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No o

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 229.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes x No o

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large Accelerated Filer xAccelerated Filer o
Non-Accelerated Filer oSmaller reporting company o
Emerging growth company o

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes o No x

As of September 30, 2026, Abbott Laboratories had 1,731,941,601 common shares without par value outstanding.

Abbott Laboratories

Table of Contents

Part I - Financial Information
Page
Item 1. Financial Statements and Supplementary Data
Condensed Consolidated Statement of Earnings3
Condensed Consolidated Statement of Comprehensive Income4
Condensed Consolidated Balance Sheet5
Condensed Consolidated Statement of Shareholders’ Investment6
Condensed Consolidated Statement of Cash Flows8
Notes to the Condensed Consolidated Financial Statements9
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations27
Item 4. Controls and Procedures34
Part II - Other Information34
Item 1. Legal Proceedings34
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds34
Item 6. Exhibits36
Signature37

Abbott Laboratories and Subsidiaries

Condensed Consolidated Statement of Earnings

(Unaudited)

(dollars in millions except per share data; shares in thousands)

Three Months EndedNine Months Ended
September 30September 30
2026202520262025
Net sales$13,013$11,369$36,770$32,869
Cost of products sold, excluding amortization of intangible assets5,6285,07515,84314,397
Amortization of intangible assets8414201,9211,260
Research and development9207662,5792,207
Selling, general, and administrative4,2663,05112,0319,203
Total operating cost and expenses11,6559,31232,37427,067
Operating earnings1,3582,0574,3965,802
Interest expense350121875373
Interest (income)(53)(77)(211)(230)
Net foreign exchange (gain) loss(6)(17)(15)(35)
Other (income) expense, net(164)(150)(457)(414)
Earnings before taxes1,2312,1804,2046,108
Taxes on earnings3115361,2791,360
Net Earnings$920$1,644$2,925$4,748
Basic Earnings Per Common Share$0.53$0.94$1.67$2.72
Diluted Earnings Per Common Share$0.53$0.94$1.67$2.70
Average Number of Common Shares Outstanding Used for Basic Earnings Per Common Share1,734,4461,742,1421,739,0801,741,617
Dilutive Common Stock Options3,4607,2193,5387,544
Average Number of Common Shares Outstanding Plus Dilutive Common Stock Options1,737,9061,749,3611,742,6181,749,161
Outstanding Common Stock Options Having No Dilutive Effect11,7301,4439,9001,431

The accompanying notes to the condensed consolidated financial statements are an integral part of this statement.

Abbott Laboratories and Subsidiaries

Condensed Consolidated Statement of Comprehensive Income

(Unaudited)

(dollars in millions)

Three Months EndedNine Months Ended
September 30September 30
2026202520262025
Net Earnings$920$1,644$2,925$4,748
Foreign currency translation gain (loss) adjustments, net of taxes of $(3) and $(9) in 2026 and $(6) and $52 in 2025(133)(136)(462)1,414
Net actuarial gains (losses) and amortization of net actuarial losses and prior service costs and credits, net of taxes of $1 and $3 in 2026 and $— and $— in 20252(11)(10)45
Net gains (losses) for derivative instruments designated as cash flow hedges, net of taxes of $— and $45 in 2026 and $8 and $(101) in 2025—39130(237)
Other comprehensive income (loss)(131)(108)(342)1,222
Comprehensive Income$789$1,536$2,583$5,970
September 30, 2026December 31, 2025
Supplemental Accumulated Other Comprehensive Income (Loss) Information, net of tax:
Cumulative foreign currency translation (loss) adjustments$(6,393)$(5,931)
Net actuarial (losses) and prior service (costs) and credits(11)(1)
Cumulative gains (losses) on derivative instruments designated as cash flow hedges61(69)
Accumulated other comprehensive income (loss)$(6,343)$(6,001)

The accompanying notes to the condensed consolidated financial statements are an integral part of this statement.

Abbott Laboratories and Subsidiaries

Condensed Consolidated Balance Sheet

(Unaudited)

(dollars in millions)

September 30, 2026December 31, 2025
Assets
Current Assets:
Cash and cash equivalents$4,052$8,522
Short-term investments246417
Trade receivables, less allowances of $508 in 2026 and $490 in 20259,0327,929
Inventories:
Finished products4,5053,976
Work in process1,027904
Materials1,8051,608
Total inventories7,3376,488
Prepaid expenses and other receivables2,8292,640
Total Current Assets23,49625,996
Investments1,099918
Property and equipment, at cost26,71425,222
Less: accumulated depreciation and amortization13,83413,406
Net property and equipment12,88011,816
Intangible assets, net of amortization19,5915,526
Goodwill32,64324,035
Deferred income taxes and other assets18,53818,422
$108,247$86,713
Liabilities and Shareholders’ Investment
Current Liabilities:
Trade accounts payable$4,656$4,240
Salaries, wages, and commissions1,8961,745
Other accrued liabilities6,5835,812
Dividends payable1,0941,097
Income taxes payable215569
Current portion of long-term debt1,7083,033
Total Current Liabilities16,15216,496
Long-term debt29,4519,896
Post-employment obligations, deferred income taxes, and other long-term liabilities11,0217,550
Commitments and Contingencies
Shareholders’ Investment:
Preferred shares, one dollar par value Authorized — 1,000,000 shares, none issued——
Common shares, without par value Authorized — 2,400,000,000 shares Issued at stated capital amount — Shares: 2026: 1,999,047,835; 2025: 1,996,795,52525,64525,527
Common shares held in treasury, at cost — Shares: 2026: 267,106,234; 2025: 260,196,074(17,913)(17,177)
Earnings employed in the business49,63849,781
Accumulated other comprehensive income (loss)(6,343)(6,001)
Total Abbott Shareholders’ Investment51,02752,130
Noncontrolling interests596641
Total Shareholders’ Investment51,62352,771
$108,247$86,713

The accompanying notes to the condensed consolidated financial statements are an integral part of this statement.

Abbott Laboratories and Subsidiaries

Condensed Consolidated Statement of Shareholders’ Investment

(Unaudited)

(in millions except shares and per share data)

Three Months Ended September 30
20262025
Common Shares:
Balance at June 30
Shares: 2026: 1,998,291,279; 2025: 1,996,448,469$25,495$25,284
Issued under incentive stock programs
Shares: 2026: 756,556; 2025: 295,3254215
Share-based compensation136120
Issuance of restricted stock awards(28)(7)
Balance at September 30
Shares: 2026: 1,999,047,835; 2025: 1,996,743,794$25,645$25,412
Common Shares Held in Treasury:
Balance at June 30
Shares: 2026: 267,907,983; 2025: 255,988,730$(17,967)$(16,610)
Issued under incentive stock programs
Shares: 2026: 802,434; 2025: 543,1005436
Purchased
Shares: 2026: 685; 2025: 2,425,492—(303)
Balance at September 30
Shares: 2026: 267,106,234; 2025: 257,871,122$(17,913)$(16,877)
Earnings Employed in the Business:
Balance at June 30$49,794$48,467
Net earnings9201,644
Cash dividends declared on common shares (per share — 2026: $0.63; 2025: $0.59)(1,095)(1,030)
Effect of common and treasury share transactions1922
Balance at September 30$49,638$49,103
Accumulated Other Comprehensive Income (Loss):
Balance at June 30$(6,212)$(6,576)
Other comprehensive income (loss)(131)(108)
Balance at September 30$(6,343)$(6,684)
Noncontrolling Interests in Subsidiaries:
Balance at June 30$652$264
Changes to noncontrolling ownership interest(30)—
Noncontrolling interests’ share of income (loss), net of distributions and share repurchases(26)46
Balance at September 30$596$310

The accompanying notes to the condensed consolidated financial statements are an integral part of this statement.

Abbott Laboratories and Subsidiaries

Condensed Consolidated Statement of Shareholders’ Investment

(Unaudited)

(in millions except shares and per share data)

Nine Months Ended September 30
20262025
Common Shares:
Balance at January 1
Shares: 2026: 1,996,795,525; 2025: 1,991,472,630$25,527$25,153
Issued under incentive stock programs
Shares: 2026: 2,252,310; 2025: 5,271,164104290
Share-based compensation623551
Issuance of restricted stock awards(609)(582)
Balance at September 30
Shares: 2026: 1,999,047,835; 2025: 1,996,743,794$25,645$25,412
Common Shares Held in Treasury:
Balance at January 1
Shares: 2026: 260,196,074; 2025: 259,774,639$(17,177)$(16,844)
Issued under incentive stock programs
Shares: 2026: 4,843,726; 2025: 4,514,000322295
Purchased
Shares: 2026: 11,753,886; 2025: 2,610,483(1,058)(328)
Balance at September 30
Shares: 2026: 267,106,234; 2025: 257,871,122$(17,913)$(16,877)
Earnings Employed in the Business:
Balance at January 1$49,781$47,261
Net earnings2,9254,748
Cash dividends declared on common shares (per share — 2026: $1.89; 2025: $1.77)(3,291)(3,091)
Effect of common and treasury share transactions223185
Balance at September 30$49,638$49,103
Accumulated Other Comprehensive Income (Loss):
Balance at January 1$(6,001)$(7,906)
Other comprehensive income (loss)(342)1,222
Balance at September 30$(6,343)$(6,684)
Noncontrolling Interests in Subsidiaries:
Balance at January 1$641$237
Changes to noncontrolling ownership interest(30)—
Noncontrolling interests’ share of income (loss), net of distributions and share repurchases(15)73
Balance at September 30$596$310

The accompanying notes to the condensed consolidated financial statements are an integral part of this statement.

Abbott Laboratories and Subsidiaries

Condensed Consolidated Statement of Cash Flows

(Unaudited)

(dollars in millions)

Nine Months Ended September 30
20262025
Cash Flow From (Used in) Operating Activities:
Net earnings$2,925$4,748
Adjustments to reconcile net earnings to net cash from operating activities —
Depreciation1,1981,064
Amortization of intangible assets1,9211,260
Share-based compensation622551
Trade receivables(904)(874)
Inventories(772)(39)
Other, net550(459)
Net Cash From Operating Activities5,5406,251
Cash Flow From (Used in) Investing Activities:
Acquisitions of property and equipment(1,409)(1,482)
Acquisitions of businesses and technologies, net of cash acquired(20,083)(85)
Sales (purchases) of other investment securities, net6146
Other4912
Net Cash From (Used in) Investing Activities(21,382)(1,509)
Cash Flow From (Used in) Financing Activities:
Net borrowings (repayments) of short-term debt and other26(44)
Proceeds from issuance of long-term debt19,8293
Repayments of long-term debt(4,154)(1,503)
Purchases of common shares(1,236)(591)
Proceeds from stock options exercised219391
Dividends paid(3,294)(3,086)
Other—(82)
Net Cash From (Used in) Financing Activities11,390(4,912)
Effect of exchange rate changes on cash and cash equivalents(18)65
Net Increase (Decrease) in Cash and Cash Equivalents(4,470)(105)
Cash and Cash Equivalents, Beginning of Year8,5227,616
Cash and Cash Equivalents, End of Period$4,052$7,511

The accompanying notes to the condensed consolidated financial statements are an integral part of this statement.

Abbott Laboratories and Subsidiaries

Notes to the Condensed Consolidated Financial Statements

September 30, 2026

(Unaudited)

Note 1 — Basis of Presentation

The accompanying unaudited, condensed consolidated financial statements have been prepared pursuant to rules and regulations of the Securities and Exchange Commission and, therefore, do not include all information and footnote disclosures normally included in audited financial statements. However, in the opinion of management, all adjustments (which include only normal adjustments) necessary to present fairly the results of operations, financial position, and cash flows have been made. These statements should be read in conjunction with the financial statements included in Abbott’s Annual Report on Form 10-K for the year ended December 31, 2025. The condensed consolidated financial statements include the accounts of the parent company, subsidiaries, and any variable interest entities for which Abbott is the primary beneficiary, after elimination of intercompany transactions.

Note 2 — New Accounting Standards

Recent Accounting Standards Not Yet Adopted

In November 2024, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) 2024-03, Income Statement (Subtopic 220-40): Reporting Comprehensive Income - Expense Disaggregation Disclosures, which requires an entity to disclose on an annual and interim basis, disaggregated information about specific income statement expense categories. The guidance should be applied prospectively with the option to apply the standard retrospectively. The standard becomes effective for Abbott for full year 2027 reporting. Abbott is currently evaluating the impact of this new standard on its consolidated financial statements.

Abbott Laboratories and Subsidiaries

Notes to the Condensed Consolidated Financial Statements

September 30, 2026

(Unaudited)

Note 3 — Revenue

Abbott’s revenues are derived primarily from the sale of a broad portfolio of healthcare products under short-term receivable arrangements. Abbott has four reportable segments: Established Pharmaceutical Products, Nutritional Products, Diagnostic Products, and Medical Devices.

The following tables provide detail by sales category:

Three Months Ended September 30, 2026Three Months Ended September 30, 2025
(in millions)U.S.Int’lTotalU.S.Int’lTotal
Established Pharmaceutical Products —
Key Emerging Markets$—$1,195$1,195$—$1,097$1,097
Other—419419—414414
Total—1,6141,614—1,5111,511
Nutritional Products —
Pediatric Nutritionals5774861,063520457977
Adult Nutritionals3818181,1993688081,176
Total9581,3042,2628881,2652,153
Diagnostic Products —
Core Laboratory3891,0491,4383669981,364
Rapid and Molecular526373899520369889
Cancer Diagnostics93830968———
Total1,8531,4523,3058861,3672,253
Medical Devices —
Rhythm Management380372752350336686
Electrophysiology429444873363397760
Heart Failure3038438728086366
Vascular290496786280465745
Structural Heart228364592256324580
Neuromodulation1856625119658254
Diabetes Care8721,3132,1857961,2612,057
Total2,6873,1395,8262,5212,9275,448
Other6—64—4
Total$5,504$7,509$13,013$4,299$7,070$11,369

Abbott Laboratories and Subsidiaries

Notes to the Condensed Consolidated Financial Statements

September 30, 2026

(Unaudited)

Note 3 — Revenue (Continued)

Nine Months Ended September 30, 2026Nine Months Ended September 30, 2025
(in millions)U.S.Int’lTotalU.S.Int’lTotal
Established Pharmaceutical Products —
Key Emerging Markets$—$3,448$3,448$—$3,121$3,121
Other—1,0911,091—1,0331,033
Total—4,5394,539—4,1544,154
Nutritional Products —
Pediatric Nutritionals1,6131,4283,0411,6951,3773,072
Adult Nutritionals1,0602,3223,3821,1052,3343,439
Total2,6733,7506,4232,8003,7116,511
Diagnostic Products —
Core Laboratory1,1133,0154,1281,0492,8503,899
Rapid and Molecular1,3841,0822,4661,5191,0622,581
Cancer Diagnostics1,921621,983———
Total4,4184,1598,5772,5683,9126,480
Medical Devices —
Rhythm Management1,0961,0832,1799949501,944
Electrophysiology1,2271,2952,5221,0581,1322,190
Heart Failure9082691,1778242491,073
Vascular8751,4912,3668311,3812,212
Structural Heart6771,0901,7677539391,692
Neuromodulation551203754565171736
Diabetes Care2,5563,8976,4532,3383,5275,865
Total7,8909,32817,2187,3638,34915,712
Other13—1312—12
Total$14,994$21,776$36,770$12,743$20,126$32,869

Notes:Abbott's Amplatzer Amulet Left Atrial Appendage Occluder device and related accessories were transferred from Structural Heart to Electrophysiology on January 1, 2026. As a result, $55 million of sales in the third quarter of 2025 and $156 million of sales in the first nine months of 2025 were moved from Structural Heart to Electrophysiology.
Beginning in 2026, Abbott aggregated its previously reported Rapid Diagnostics, Molecular Diagnostics, and Point of Care businesses into the Rapid and Molecular Diagnostics business.
On March 23, 2026, Abbott completed the acquisition of Exact Sciences Corporation (Exact Sciences). Following the acquisition, the sales of Exact Sciences are presented as Cancer Diagnostics.

Abbott Laboratories and Subsidiaries

Notes to the Condensed Consolidated Financial Statements

September 30, 2026

(Unaudited)

Note 3 — Revenue (Continued)

Remaining Performance Obligations

As of September 30, 2026, the estimated revenue expected to be recognized in the future related to performance obligations that are unsatisfied (or partially unsatisfied) was approximately $6.2 billion in the Diagnostic Products segment, $480 million in the Medical Devices segment, and $240 million in the Established Pharmaceutical Products segment. Abbott expects to recognize revenue on approximately 52 percent of these remaining performance obligations over the next 24 months, approximately 18 percent over the subsequent 12 months, and the remainder thereafter.

These performance obligations primarily reflect the future sale of products in contracts with minimum purchase obligations, extended warranty or service obligations related to previously sold equipment, and remote monitoring services related to previously implanted devices. Abbott has applied the practical expedient described in FASB Accounting Standards Codification (ASC) 606-10-50-14 and has not included remaining performance obligations related to contracts with original expected durations of one year or less in the amounts above.

Other Contract Assets and Liabilities

Abbott discloses Trade receivables separately in the Condensed Consolidated Balance Sheet at the net amount expected to be collected. Contract assets primarily relate to Abbott’s conditional right to consideration for work completed but not billed at the reporting date. Contract assets at the beginning and the end of the period, as well as the changes in the balance, were not significant.

Contract liabilities primarily relate to payments received from customers in advance of performance under the contract. Abbott’s contract liabilities arise primarily in the Medical Devices segment when payment is received upfront for various multi-period extended service arrangements.

Changes in the contract liabilities during the period are as follows:

(in millions)
Contract Liabilities:
Balance at December 31, 2025$633
Unearned revenue from cash received during the period394
Revenue recognized related to contract liability balance(358)
Balance at September 30, 2026$669

Note 4 — Supplemental Financial Information

Shares of unvested restricted stock that contain non-forfeitable rights to dividends are treated as participating securities and are included in the computation of earnings per share under the two-class method. Under the two-class method, net earnings are allocated between common shares and participating securities. Net earnings allocated to common shares for the three months ended September 30, 2026, and 2025, were $0.9 billion and $1.6 billion, respectively, and for the nine months ended September 30, 2026, and 2025, were $2.9 billion and $4.7 billion, respectively.

Other, net in Net Cash From Operating Activities in the Condensed Consolidated Statement of Cash Flows for the first nine months of 2026 includes the payment of cash taxes of $1.3 billion. The first nine months of 2025 included $256 million of pension contributions and the payment of cash taxes of $1.5 billion.

Abbott Laboratories and Subsidiaries

Notes to the Condensed Consolidated Financial Statements

September 30, 2026

(Unaudited)

Note 4 — Supplemental Financial Information (Continued)

The following summarizes the activity for the first nine months of 2026 related to the allowance for doubtful accounts as of September 30, 2026:

(in millions)
Allowance for Doubtful Accounts:
Balance at December 31, 2025$290
Provisions/charges to income82
Amounts charged off and other deductions(46)
Balance at September 30, 2026$326

The allowance for doubtful accounts reflects the current estimate of credit losses expected to be incurred over the life of the accounts receivable. Abbott considers various factors in establishing, monitoring, and adjusting its allowance for doubtful accounts, including the aging of the accounts and aging trends, the historical level of charge-offs, and specific exposures related to particular customers. Abbott also monitors other risk factors and forward-looking information, such as country risk, when determining credit limits for customers and establishing adequate allowances.

The components of long-term investments are as follows:

(in millions)September 30, 2026December 31, 2025
Long-term Investments:
Equity securities$811$597
Other288321
Total$1,099$918

The increase in Abbott’s long-term investments as of September 30, 2026, compared to December 31, 2025, primarily reflects non-marketable securities acquired in the Exact Sciences acquisition and other investment activity during the period.

Abbott’s equity securities as of September 30, 2026, include $318 million of investments in mutual funds that are held in a rabbi trust. These investments, which are specifically designated as available for the purpose of paying benefits under a deferred compensation plan, are not available for general corporate purposes and are subject to creditor claims in the event of insolvency.

Abbott holds certain investments as of September 30, 2026, including investments accounted for under the equity method with a carrying value of $173 million and other equity investments with a carrying value of $238 million that do not have a readily determinable fair value.

Abbott Laboratories and Subsidiaries

Notes to the Condensed Consolidated Financial Statements

September 30, 2026

(Unaudited)

Note 5 — Changes In Accumulated Other Comprehensive Income (Loss)

The changes in Accumulated other comprehensive income (loss), net of tax, are as follows:

Three Months Ended September 30
Cumulative Foreign Currency Translation (Loss) AdjustmentsNet Actuarial (Losses) and Prior Service (Costs) and CreditsCumulative Gains (Losses) on Derivative Instruments Designated as Cash Flow Hedges
(in millions)202620252026202520262025
Balance at June 30$(6,260)$(5,955)$(13)$(555)$61$(66)
Other comprehensive income (loss) before reclassifications(133)(136)(1)(11)(10)28
Amounts reclassified from accumulated other comprehensive income——3—1011
Net current period comprehensive income (loss)(133)(136)2(11)—39
Balance at September 30$(6,393)$(6,091)$(11)$(566)$61$(27)
Nine Months Ended September 30
Cumulative Foreign Currency Translation (Loss) AdjustmentsNet Actuarial (Losses) and Prior Service (Costs) and CreditsCumulative Gains (Losses) on Derivative Instruments Designated as Cash Flow Hedges
(in millions)202620252026202520262025
Balance at January 1$(5,931)$(7,505)$(1)$(611)$(69)$210
Other comprehensive income (loss) before reclassifications(462)1,414(20)4519(186)
Amounts reclassified from accumulated other comprehensive income——10—111(51)
Net current period comprehensive income (loss)(462)1,414(10)45130(237)
Balance at September 30$(6,393)$(6,091)$(11)$(566)$61$(27)

Reclassified amounts for cash flow hedges are recorded as Cost of products sold. Net actuarial losses and prior service cost are included as a component of net periodic benefit costs; see Note 13 — Post-Employment Benefits for additional details.

Abbott Laboratories and Subsidiaries

Notes to the Condensed Consolidated Financial Statements

September 30, 2026

(Unaudited)

Note 6 — Business Acquisition

On March 23, 2026, Abbott completed the acquisition of Exact Sciences for approximately $20.6 billion. The acquisition was funded primarily through the issuance of $20.0 billion of long-term debt in March 2026, with the remainder funded with cash on hand. Under the terms of the agreement, Abbott paid $105 per common share in cash. As part of the acquisition, Abbott assumed approximately $2.8 billion of Exact Sciences’ debt, nearly all of which was repaid. The acquisition of Exact Sciences has established Abbott's position in the cancer diagnostics market and expands its portfolio to include products such as Cologuard®, Oncotype DX®, and Cancerguard®.

The preliminary allocation of the fair value of the Exact Sciences acquisition is shown in the table below. During the third quarter of 2026, Abbott recorded measurement period adjustments, including a $3.2 billion increase in acquired intangible assets with a corresponding reduction to goodwill, which resulted in approximately $100 million of additional amortization expense recognized in the third quarter. Allocation of the purchase price of the acquisition will be finalized when the valuation of assets and liabilities is completed. The differences between the preliminary and final allocation could be material.

(in billions)
Acquired intangible assets, non-deductible$16.0
Goodwill, non-deductible8.9
Acquired net tangible assets0.4
Deferred income taxes recorded at acquisition(2.7)
Net debt(2.0)
Total preliminary allocation of fair value$20.6

The goodwill is primarily attributable to future growth opportunities, assembled workforce, potential future technologies, and other intangible assets that do not qualify for separate recognition, as well as expected synergies from combining operations. The acquired net tangible assets consist primarily of property and equipment, trade accounts receivable, trade accounts payable, other current liabilities, and other non-current liabilities.

If the acquisition had occurred as of the beginning of 2025, unaudited pro forma consolidated net sales would have been approximately $12.2 billion and $35.2 billion for the three and nine months ended September 30, 2025, respectively. Unaudited pro forma earnings before taxes for the three months ended September 30, 2025, would have been approximately $1.6 billion, reflecting interest expense of $0.2 billion and amortization expense related to acquired intangible assets of $0.4 billion. Unaudited pro forma earnings before taxes for the nine months ended September 30, 2025, would have been approximately $3.7 billion, reflecting transaction-related expenses of $0.5 billion, interest expense of $0.7 billion, and amortization expense related to acquired intangible assets of $1.1 billion. Unaudited pro forma consolidated net sales would have been approximately $13.0 billion and $37.5 billion for the three and nine months ended September 30, 2026, respectively. Unaudited pro forma earnings before taxes would have been approximately $1.4 billion for the three months ended September 30, 2026. For the nine months ended September 30, 2026, unaudited pro forma earnings before taxes would have been approximately $4.1 billion, after the effect of interest expense of $0.2 billion, amortization expense related to acquired intangible assets of $0.3 billion, and excluding transaction-related expenses of $0.5 billion that were directly attributable to the acquisition. The unaudited pro forma information is not necessarily indicative of the consolidated results of operations that would have been realized had the Exact Sciences acquisition been completed as of the beginning of 2025, nor is it intended to be indicative of future results of operations of the combined entity.

In the first nine months of 2026, Abbott's condensed consolidated results include $2.0 billion of net sales related to Exact Sciences. Earnings of Exact Sciences included in Abbott's condensed consolidated financial statements since the acquisition date are not material to Abbott's consolidated net earnings.

Abbott Laboratories and Subsidiaries

Notes to the Condensed Consolidated Financial Statements

March 31, 2025

(Unaudited)

Note 7 — Goodwill and Intangible Assets

The total amount of goodwill reported was $32.6 billion at September 30, 2026, and $24.0 billion at December 31, 2025. Goodwill increased by $8.9 billion in the first nine months of 2026 due to the completion of the Exact Sciences acquisition. Foreign currency translation adjustments decreased goodwill by $0.3 billion in the first nine months of 2026. The amount of goodwill related to reportable segments at September 30, 2026, was $2.7 billion for the Established Pharmaceutical Products segment, $0.3 billion for the Nutritional Products segment, $12.5 billion for the Diagnostic Products segment, and $17.2 billion for the Medical Devices segment. The Diagnostic Products segment includes the amount of goodwill related to the Exact Sciences acquisition. There were no reductions of goodwill relating to impairments in the first nine months of 2026.

The gross amount of amortizable intangible assets, primarily product rights and technology, was $43.5 billion as of September 30, 2026, and $27.6 billion as of December 31, 2025. The gross amount of amortizable intangible assets increased by $16.0 billion in the first nine months of 2026 due to the completion of the Exact Sciences acquisition. Accumulated amortization was $25.1 billion and $23.3 billion as of September 30, 2026, and December 31, 2025, respectively. Abbott’s estimated annual amortization expense for intangible assets is approximately $3.0 billion in 2026, $2.7 billion in 2027, $2.1 billion in 2028, $2.1 billion in 2029, and $1.9 billion in 2030.

Indefinite-lived intangible assets, which relate to in-process research and development (IPR&D), were $1.2 billion as of September 30, 2026, and December 31, 2025.

Note 8 — Restructuring Plans

In 2025, Abbott management approved plans to streamline operations in order to reduce costs and improve efficiencies in its diagnostics and medical devices businesses. In addition, Abbott recognized asset impairment charges of $25 million related to these restructuring plans in the first nine months of 2025. The following summarizes the activity related to these restructuring actions and the status of the related accruals as of September 30, 2026:

(in millions)Total
Accrued balance at December 31, 2025$180
Payments and other adjustments(92)
Accrued balance at September 30, 2026$88

Note 9 — Incentive Stock Programs

In the first nine months of 2026, Abbott granted 2,011,741 stock options, 449,237 restricted stock awards, and 5,090,970 restricted stock units under its incentive stock program. At September 30, 2026, approximately 140 million shares were reserved for future grants. This reserve reflects the shares authorized by Abbott's shareholders in April 2026. Information regarding the number of options outstanding and exercisable at September 30, 2026, is as follows:

OutstandingExercisable
Number of shares22,221,49718,707,816
Weighted average remaining life (years)4.63.8
Weighted average exercise price$96.60$92.10
Aggregate intrinsic value (in millions)$284$284

In connection with the completion of the Exact Sciences acquisition, unvested Exact Sciences restricted stock units were converted into Abbott restricted stock units, in accordance with the merger agreement. The number of restricted stock units converted was 1,476,916 at a fair value of $105.62.

The total unrecognized share-based compensation cost at September 30, 2026, amounted to $641 million, which is expected to be recognized over approximately the next three years.

Abbott Laboratories and Subsidiaries

Notes to the Condensed Consolidated Financial Statements

September 30, 2026

(Unaudited)

Note 10 — Debt and Lines of Credit

In March 2026, Abbott issued $20.0 billion of debt to finance the acquisition of Exact Sciences, as follows:

(in millions)Principal amount
SOFR+ 50 bp Senior notes due 2029$1,000
3.700% Senior notes due 2029$2,250
4.000% Senior notes due 2031$2,500
4.300% Senior notes due 2033$2,750
4.650% Senior notes due 2036$3,750
4.750% Senior notes due 2038$2,000
5.500% Senior notes due 2056$3,750
5.600% Senior notes due 2066$2,000

As part of the acquisition, Abbott assumed approximately $2.8 billion of Exact Sciences’ debt, nearly all of which was repaid.

On September 27, 2026, Abbott repaid the €1.14 billion outstanding principal amount on its 1.500% Notes upon maturity. The repayment equated to approximately $1.3 billion. On September 15, 2025, Abbott repaid the $500 million outstanding principal amount of its 3.875% Notes upon maturity. On March 17, 2025, Abbott repaid the $1.0 billion outstanding principal amount of its 2.95% Notes upon maturity.

Note 11 — Financial Instruments, Derivatives and Fair Value Measures

Certain Abbott foreign subsidiaries enter into foreign currency forward exchange contracts to manage exposures to changes in foreign exchange rates, primarily for anticipated intercompany purchases by those subsidiaries whose functional currencies are not the U.S. dollar. These contracts, with gross notional amounts totaling $8.2 billion at September 30, 2026, and $7.4 billion at December 31, 2025, are designated as cash flow hedges of the variability of the cash flows due to changes in foreign exchange rates and are recorded at fair value. Accumulated gains and losses as of September 30, 2026, will be included in Cost of products sold at the time the products are sold, generally through the next twelve to eighteen months.

Abbott enters into foreign currency forward exchange contracts to manage currency exposures for foreign currency denominated third-party trade payables and receivables, and for intercompany loans and trade accounts payable where the receivable or payable is denominated in a currency other than the functional currency of the entity. For intercompany loans, the contracts require Abbott to sell or buy foreign currencies, primarily European currencies, in exchange for primarily U.S. dollars and other European currencies. For intercompany and trade payables and receivables, the currency exposures are primarily the U.S. dollar and European currencies. At September 30, 2026, and December 31, 2025, Abbott held gross notional amounts of $12.8 billion and $13.1 billion, respectively, of such foreign currency forward exchange contracts.

Abbott has designated a yen-denominated, 5-year term loan of $584 million and $589 million as of September 30, 2026, and December 31, 2025, respectively, as a hedge of the net investment in certain foreign subsidiaries. The change in the value of the debt, which is due to changes in foreign exchange rates, is recorded in Accumulated other comprehensive income (loss), net of tax.

Abbott Laboratories and Subsidiaries

Notes to the Condensed Consolidated Financial Statements

September 30, 2026

(Unaudited)

Note 11 — Financial Instruments, Derivatives and Fair Value Measures (Continued)

Abbott is a party to interest rate hedge contracts to manage its exposure to changes in the fair value of fixed-rate debt. These contracts are designated as fair value hedges of the variability of the fair value of fixed-rate debt due to changes in the long-term benchmark interest rates. The effect of the hedge is to change a fixed-rate interest obligation to a variable rate for that portion of the debt. Abbott records the contracts at fair value and adjusts the carrying amount of the fixed-rate debt by an offsetting amount. At September 30, 2026, and December 31, 2025, Abbott had interest rate hedge contracts with a notional amount totaling $4.2 billion and $1.2 billion, respectively. The increase from December 31, 2025, was due to additional interest rate hedge contracts associated with fixed-rate debt issued as part of the Exact Sciences acquisition.

The following table summarizes the amounts and location of certain derivative and non-derivative financial instruments as of September 30, 2026, and December 31, 2025:

Fair Value - AssetsFair Value - Liabilities
(in millions)September 30, 2026December 31, 2025Balance Sheet CaptionSeptember 30, 2026December 31, 2025Balance Sheet Caption
Interest rate swaps designated as fair value hedges:
Non-current$—$—Deferred income taxes and other assets$267$—Post-employment obligations, deferred income taxes, and other long-term liabilities
Current——Prepaid expenses and other receivables1219Other accrued liabilities
Foreign currency forward exchange contracts:
Hedging instruments13957Prepaid expenses and other receivables94231Other accrued liabilities
Others not designated as hedges7651Prepaid expenses and other receivables8866Other accrued liabilities
Debt designated as a hedge of net investment in a foreign subsidiary——n/a584589Long-term debt
$215$108$1,045$905

Abbott Laboratories and Subsidiaries

Notes to the Condensed Consolidated Financial Statements

September 30, 2026

(Unaudited)

Note 11 — Financial Instruments, Derivatives and Fair Value Measures (Continued)

The following table summarizes the activity for foreign currency forward exchange contracts designated as cash flow hedges and certain other derivative financial instruments, as well as the amounts and location of income (expense) and gain (loss) reclassified into income:

Gain (loss) Recognized in Other Comprehensive Income (loss)Income (expense) and Gain (loss) Reclassified into Income
Three Months Ended September 30,Nine Months Ended September 30,Three Months Ended September 30,Nine Months Ended September 30,
(in millions)20262025202620252026202520262025Income Statement Caption
Foreign currency forward exchange contracts designated as cash flow hedges$(14)$33$25$(270)$(10)$(13)$(147)$74Cost of products sold
Debt designated as a hedge of net investment in a foreign subsidiary(16)165(36)————n/a
Interest rate swaps designated as fair value hedgesn/an/an/an/a(167)—(260)17Interest expense

Gains of $50 million and $9 million were recognized in the three months ended September 30, 2026, and 2025, respectively, related to foreign currency forward exchange contracts not designated as a hedge. Gains of $110 million and $44 million were recognized in the nine months ended September 30, 2026, and 2025, respectively, related to foreign currency forward exchange contracts not designated as a hedge. These amounts are reported in the Condensed Consolidated Statement of Earnings on the Net foreign exchange (gain) loss line.

The carrying values and fair values of certain financial instruments as of September 30, 2026, and December 31, 2025, are shown in the following table. The carrying values of all other financial instruments approximate their estimated fair values. The counterparties to financial instruments consist of select major international financial institutions. Abbott does not expect any losses from non-performance by these counterparties.

September 30, 2026December 31, 2025
(in millions)Carrying ValueFair ValueCarrying ValueFair Value
Long-term Investment Securities:
Equity securities$811$811$597$597
Other288288321321
Total Long-term Debt(31,159)(28,657)(12,929)(12,772)
Foreign Currency Forward Exchange Contracts:
Receivable position215215108108
(Payable) position(182)(182)(297)(297)
Interest Rate Hedge Contracts:
Receivable position————
(Payable) position(279)(279)(19)(19)

The fair value of the debt was determined based on significant other observable inputs, including current interest rates.

Abbott Laboratories and Subsidiaries

Notes to the Condensed Consolidated Financial Statements

September 30, 2026

(Unaudited)

Note 11 — Financial Instruments, Derivatives and Fair Value Measures (Continued)

The following table summarizes the bases used to measure certain assets and liabilities at fair value on a recurring basis in the balance sheet:

Basis of Fair Value Measurement
(in millions)Outstanding BalancesQuoted Prices in Active MarketsSignificant Other Observable InputsSignificant Unobservable Inputs
September 30, 2026:
Equity securities$400$400$—$—
Foreign currency forward exchange contracts215—215—
Total Assets$615$400$215$—
Fair value of hedged long-term debt$3,879$—$3,879$—
Interest rate swap derivative financial instruments279—279—
Foreign currency forward exchange contracts182—182—
Contingent consideration256——256
Total Liabilities$4,596$—$4,340$256
December 31, 2025:
Equity securities$342$342$—$—
Foreign currency forward exchange contracts108—108—
Total Assets$450$342$108$—
Fair value of hedged long-term debt$1,133$—$1,133$—
Interest rate swap derivative financial instruments19—19—
Foreign currency forward exchange contracts297—297—
Contingent consideration1——1
Total Liabilities$1,450$—$1,449$1

The fair value of foreign currency forward exchange contracts is determined using a market approach, which utilizes values for comparable derivative instruments. The fair value of debt was determined based on the face value of the debt adjusted for the fair value of the interest rate swaps, which is based on a discounted cash flow analysis using significant other observable inputs. The fair value of contingent consideration is determined using valuation techniques that incorporate significant unobservable inputs and management estimates regarding the probability and timing of future payments. The increase in the amount of contingent consideration from December 31, 2025, reflects contingent consideration assumed with the acquisition of Exact Sciences.

Abbott Laboratories and Subsidiaries

Notes to the Condensed Consolidated Financial Statements

September 30, 2026

(Unaudited)

Note 12 — Litigation and Environmental Matters

Abbott has been identified as a potentially responsible party for investigation and cleanup costs at a number of locations in the United States and Puerto Rico under federal and state remediation laws and is investigating potential contamination at a number of company-owned locations. Abbott has recorded an estimated cleanup cost for each site for which management believes Abbott has a probable loss exposure. No individual site cleanup exposure is expected to exceed $4 million, and the aggregate cleanup exposure is not expected to exceed $10 million.

Abbott has been named as a defendant in a number of lawsuits alleging that its preterm infant formula and human milk fortifier products that contain cow’s milk ingredients cause an intestinal disease known as necrotizing enterocolitis (NEC) and inadequately warn about the risk of NEC. These lawsuits claim that certain preterm infants suffered injury or death as a result of contracting NEC. Several of these matters have progressed to a decision, with varying outcomes. In the first three federal Multidistrict Litigation (MDL) “bellwether” cases before the U.S. District Court for the Northern District of Illinois, Abbott prevailed on summary judgment. Outcomes in the state court cases have varied, ranging from a summary judgment ruling in Abbott’s favor to a plaintiff verdict awarding $495 million in damages (the "Gill case"). Several of these cases are at various stages of appeal. During the third quarter of 2026, Abbott recorded a charge of approximately $670 million related to agreements to resolve the Gill case and the NEC claims brought on behalf of approximately 2,000 additional infants. These agreements are a compromise of disputed claims and not in any way an admission of liability. Abbott stands by its products and the information it provided about them. Given the uncertainty as to the possible outcome of the remaining NEC-related matters, Abbott is unable to reasonably estimate a range of possible loss related to these matters and, therefore, no additional reserves have been recorded.

Abbott was a defendant in a civil qui tam lawsuit related to its U.S. manufacturing of powdered infant formula products. In that matter, the U.S. Department of Justice (DOJ) and several states had partially intervened, alleging violations of certain federal and state laws, including the Federal False Claims Act. In September 2026, Abbott reached an agreement to resolve the DOJ investigations and the aforementioned complaints, pursuant to which Abbott paid approximately $385 million, plus attorneys' fees and accrued interest, to resolve all claims. The settlement does not represent any finding of fault or liability, and no evidence was found that Abbott infant formula products caused the illnesses or deaths that prompted Abbott’s voluntary recall in 2022.

Abbott is involved in various claims and legal proceedings. Abbott estimates the range of possible loss for all of its various legal proceedings and environmental exposures to be from approximately $430 million to $450 million. The recorded accrual balance at September 30, 2026, for these proceedings and exposures was approximately $435 million. This accrual represents management’s best estimate of probable loss, as defined by FASB ASC No. 450, “Contingencies.” Within the next year, legal proceedings may occur that could result in a change in the estimated loss accrued by Abbott. While it is not feasible to predict the outcome of all such proceedings and exposures with certainty, management believes that their ultimate disposition should not have a material adverse effect on Abbott’s financial position, cash flows, or results of operations, except for the matters discussed in the second paragraph of this note, the resolution of which could be material to Abbott’s financial position, cash flows, or results of operations.

Abbott Laboratories and Subsidiaries

Notes to the Condensed Consolidated Financial Statements

September 30, 2026

(Unaudited)

Note 13 — Post-Employment Benefits

Retirement plans consist of defined benefit, defined contribution, and medical and dental plans. Net periodic benefit costs, other than service costs, are recognized in the Other (income) expense, net line of the Condensed Consolidated Statement of Earnings. Net costs recognized for Abbott’s major defined benefit plans and post-employment medical and dental benefit plans are as follows:

Defined Benefit PlansMedical and Dental Plans
Three Months Ended September 30,Nine Months Ended September 30,Three Months Ended September 30,Nine Months Ended September 30,
(in millions)20262025202620252026202520262025
Service cost - benefits earned during the period$52$55$156$162$12$11$35$32
Interest cost on projected benefit obligations12412437236918175451
Expected return on plan assets(295)(282)(887)(841)(9)(7)(26)(20)
Net amortization of:
Actuarial loss, net12462—5—
Prior service cost (credit)——11—(2)—(7)
Net cost (credit)$(118)$(101)$(354)$(303)$23$19$68$56

Abbott funds its domestic defined benefit plans according to U.S. Internal Revenue Service (IRS) funding limitations. International pension plans are funded according to similar regulations. In the first nine months of 2026 and 2025, $110 million and $75 million were contributed, respectively, to the post-employment medical and dental plans. In the first nine months of 2025, $256 million was contributed to defined benefit plans.

Note 14 — Taxes on Earnings

Taxes on earnings reflect the estimated annual effective rates and include charges for interest and penalties. In the first nine months of 2026 and 2025, taxes on earnings included $28 million and $91 million, respectively, in excess tax benefits associated with share-based compensation. In the first nine months of 2026 and 2025, taxes on earnings included approximately $540 million and $460 million, respectively, of tax expense related to a deferred tax asset that was recognized as a significant non-cash tax benefit in a prior year. In the first nine months of 2026 and 2025, taxes on earnings also included approximately $95 million of net tax expense and $90 million of net tax benefit, respectively, primarily as the result of the resolution of various tax positions related to prior years.

In September 2023, Abbott received a Statutory Notice of Deficiency (SNOD) from the IRS for the 2019 Federal tax year in the amount of $417 million. The primary adjustments proposed in the SNOD relate to the reallocation of income between Abbott’s U.S. entities and its foreign affiliates. Abbott believes that the income reallocation adjustments proposed in the SNOD are without merit, in part because certain adjustments contradict methods that were agreed to with the IRS in prior audit periods. The SNOD also contains other proposed adjustments that Abbott believes are erroneous and unsupported. Abbott filed a petition with the U.S. Tax Court contesting the SNOD in December 2023.

In June 2024, Abbott received a SNOD from the IRS for the 2017 and 2018 Federal tax years in the amount of $192 million. The matters proposed in the 2017/2018 SNOD are substantially similar to the income allocation adjustments included in the 2019 SNOD. Abbott filed a petition in September 2024 with the U.S. Tax Court contesting the 2017/2018 SNOD in a manner consistent with its petition for the 2019 SNOD.

Abbott Laboratories and Subsidiaries

Notes to the Condensed Consolidated Financial Statements

September 30, 2026

(Unaudited)

Note 14 — Taxes on Earnings (Continued)

In October 2024, Abbott received a SNOD from the IRS for the 2020 Federal tax year assessing an additional $443 million of income tax. The primary adjustments proposed in the SNOD are substantially similar to the income allocation adjustments included in the 2017/2018 and 2019 SNODs. Abbott believes that the income reallocation adjustments proposed in the SNOD are without merit. The SNOD also contains other proposed adjustments and omissions that Abbott believes are erroneous and unsupported. In addition to the tax assessment for the 2020 tax year, the 2020 SNOD also contested a deduction for which an estimated $440 million cash tax benefit would be available in a different taxable year as allowed under applicable U.S. tax law. Abbott filed a petition with the U.S. Tax Court contesting the SNOD in December 2024.

Abbott and the IRS are in active discussions regarding several of the disputed items contained in the 2017 – 2020 SNODs.

In July 2024, Abbott received a $413 million tax assessment from the Malaysian tax authorities for the 2023 tax year. The assessment applies a property capital gains tax on the value of the shares associated with the intercompany sale of an affiliate. Abbott believes the assessment of the Malaysian tax authority to be without merit. In October 2025, the Penang High Court upheld the assessment of the Malaysian tax authority. In October 2025, Abbott filed an appeal with the Malaysian Court of Appeals.

There are numerous other income tax jurisdictions for which tax returns are not yet settled, none of which Abbott expects to be individually significant. Abbott intends to vigorously defend its filing positions in all jurisdictions in which it has unresolved tax matters through ongoing discussions with taxing administrations and/or through litigation as necessary. Abbott reserves for uncertain tax positions related to unresolved tax matters where Abbott’s tax filing position does not meet the standard for recognition of an income tax benefit. Abbott continues to believe that the amount of its recorded reserves for uncertain tax positions is appropriate. Reserves for interest and penalties are not significant.

The Organization for Economic Cooperation & Development (OECD) has proposed a two-pillared plan for a revised international tax system. Pillar 1 proposes to reallocate taxing rights among the jurisdictions in which in-scope multinational corporations operate. Pillar 2 proposes to assess a 15 percent minimum tax on the earnings of in-scope multinational corporations on a country-by-country basis. Numerous countries have enacted legislation to adopt the Pillar 2 model rules. On January 5, 2026, the OECD released administrative guidance that, when enacted, exempts U.S.-parented groups from the Pillar 2 minimum tax. Abbott continues to monitor legislative developments and assess any potential impacts on Abbott's operations for both the Pillar 1 and Pillar 2 proposals.

Abbott Laboratories and Subsidiaries

Notes to the Condensed Consolidated Financial Statements

September 30, 2026

(Unaudited)

Note 15 — Segment Information

Abbott’s principal business is the discovery, development, manufacture, and sale of a broad portfolio of healthcare products. Abbott’s products are generally sold directly to retailers, wholesalers, consumers, hospitals, healthcare facilities, laboratories, health systems, and government agencies throughout the world. On March 23, 2026, Abbott completed its acquisition of Exact Sciences. From the acquisition date, Abbott's results include Exact Sciences' results, which are reported within the Diagnostic Products segment as Cancer Diagnostics.

Abbott’s reportable segments are as follows:

Established Pharmaceutical Products — International sales of a broad line of branded generic pharmaceutical and biologic products.

Nutritional Products — Worldwide sales of a broad line of adult and pediatric nutritional products.

Diagnostic Products — Worldwide sales of diagnostic systems, tests, and automated solutions. For segment reporting purposes, the Core Laboratory Diagnostics, Rapid and Molecular Diagnostics, and Cancer Diagnostics businesses are aggregated and reported as the Diagnostic Products segment.

Medical Devices — Worldwide sales of rhythm management, electrophysiology, heart failure, vascular, structural heart, neuromodulation, and diabetes care products. For segment reporting purposes, the Rhythm Management, Electrophysiology, Heart Failure, Vascular, Structural Heart, Neuromodulation, and Diabetes Care businesses are aggregated and reported as the Medical Devices segment.

Abbott’s underlying accounting records are maintained on a legal entity basis for government and public reporting requirements. Segment disclosures are on a performance basis consistent with internal management reporting. The chief operating decision maker (CODM) at Abbott is the Chief Executive Officer. The CODM primarily considers sales and operating margin to assess the performance of segments and to allocate resources, where segment operating margin profitability includes cost of products sold and operating expenses. The cost of some corporate functions and the cost of certain employee benefits are charged to segments at predetermined rates that approximate cost. Remaining costs, if any, are not allocated to segments. In addition, intangible asset amortization and certain legal settlements are not allocated to operating segments, and intangible assets and goodwill are not included in the measure of each segment’s assets.

Abbott Laboratories and Subsidiaries

Notes to the Condensed Consolidated Financial Statements

September 30, 2026

(Unaudited)

Note 15 — Segment Information (Continued)

The following segment information has been prepared in accordance with the internal accounting policies of Abbott, as described above, and is not presented in accordance with generally accepted accounting principles applied to the condensed consolidated financial statements.

Net Sales to External CustomersCost of Products SoldResearch and DevelopmentSelling, General, and AdministrativeOperating Earnings
Three Months Ended September 30,Three Months Ended September 30,Three Months Ended September 30,Three Months Ended September 30,Three Months Ended September 30,
(in millions)2026202520262025202620252026202520262025
Established Pharmaceuticals$1,614$1,511$(732)$(714)$(47)$(42)$(376)$(364)$459$391
Nutritional Products2,2622,153(1,272)(1,223)(54)(55)(552)(515)384360
Diagnostic Products3,3052,253(1,609)(1,290)(265)(150)(762)(413)669400
Medical Devices5,8265,448(1,942)(1,767)(500)(462)(1,476)(1,390)1,9081,829
Total$13,007$11,365$(5,555)$(4,994)$(866)$(709)$(3,166)$(2,682)$3,420$2,980
Other64
Net sales$13,013$11,369
Corporate functions and plan benefit costs(85)(84)
Net interest expense(297)(44)
Share-based compensation (a)(137)(120)
Amortization of intangible assets(841)(420)
Other, net (b)(829)(132)
Earnings before Taxes$1,231$2,180
Net Sales to External CustomersCost of Products SoldResearch and DevelopmentSelling, General, and AdministrativeOperating Earnings
Nine Months Ended September 30,Nine Months Ended September 30,Nine Months Ended September 30,Nine Months Ended September 30,Nine Months Ended September 30,
(in millions)2026202520262025202620252026202520262025
Established Pharmaceuticals$4,539$4,154$(2,026)$(1,914)$(136)$(127)$(1,171)$(1,078)$1,206$1,035
Nutritional Products6,4236,511(3,509)(3,502)(162)(161)(1,689)(1,676)1,0631,172
Diagnostic Products8,5776,480(4,383)(3,666)(688)(455)(2,003)(1,228)1,5031,131
Medical Devices17,21815,712(5,681)(5,123)(1,414)(1,293)(4,353)(4,062)5,7705,234
Total$36,757$32,857$(15,599)$(14,205)$(2,400)$(2,036)$(9,216)$(8,044)$9,542$8,572
Other1312
Net sales$36,770$32,869
Corporate functions and plan benefit costs(195)(177)
Net interest expense(664)(143)
Share-based compensation (a)(943)(551)
Amortization of intangible assets(1,921)(1,260)
Other, net (b)(1,615)(333)
Earnings before Taxes$4,204$6,108

(a)Approximately 45 percent of the annual net cost of share-based awards will typically be recognized in the first quarter due to the timing of the granting of share-based awards. The first nine months of 2026 included $321 million of stock compensation expense related to the cash settlement of equity awards in connection with the Exact Sciences acquisition, per the terms of the merger agreement.
(b)Other, net for the three and nine months ended September 30, 2026, includes costs related to the acquisition of Exact Sciences and legal settlements. Other, net for the three and nine months ended September 30, 2025, includes charges related to restructurings. For the nine months ended September 30, 2025, Other, net includes a fair value adjustment to a contingent consideration.

Abbott Laboratories and Subsidiaries

Notes to the Condensed Consolidated Financial Statements

September 30, 2026

(Unaudited)

Note 15 — Segment Information (Continued)

DepreciationAdditions to Property and Equipment
Three Months Ended September 30,Three Months Ended September 30,
(in millions)2026202520262025
Established Pharmaceuticals$27$28$34$38
Nutritional Products46476271
Diagnostic Products171136180168
Medical Devices10997173140
Total Reportable Segments353308449417
Other62636370
Total$415$371$512$487
DepreciationAdditions to Property and Equipment
Nine Months Ended September 30,Nine Months Ended September 30,
(in millions)2026202520262025
Established Pharmaceuticals$82$76$90$110
Nutritional Products147133148231
Diagnostic Products480397465469
Medical Devices315279505441
Total Reportable Segments1,0248851,2081,251
Other174179194192
Total$1,198$1,064$1,402$1,443
Total Assets
(in millions)As of September 30, 2026As of December 31, 2025
Established Pharmaceuticals$3,878$3,540
Nutritional Products5,2344,791
Diagnostic Products9,9678,273
Medical Devices11,68710,689
Total Reportable Segment Assets$30,766$27,293
Cash and investments5,3979,857
Goodwill and intangible assets52,23429,561
All other (c)19,85020,002
Total Assets$108,247$86,713
(c)As of September 30, 2026, and December 31, 2025, all other includes the long-term assets associated with the defined benefit plans and certain deferred tax assets.

Note 16 — Separation of Abbott's Global Nutrition Business

In October 2026, Abbott announced its intention to separate its Nutrition business into an independent, publicly traded company. The new company's business will include the Nutritional Products segment, which includes a broad portfolio of adult and pediatric nutritional products, including the Similac®, PediaSure®, Pedialyte®, Glucerna®, and Ensure® brands. Abbott intends to separate the business through distribution of shares of the independent Nutrition company to Abbott shareholders. The transaction is intended to qualify as a tax-free separation for U.S. federal income tax purposes. Abbott expects to complete the transaction by the end of 2027, subject to customary conditions, including regulatory approvals, the effectiveness of a registration statement on Form 10 and final approval by the Abbott board of directors.

Next: Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations